11/21
02:02 pm
zyme
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Low
Report
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
11/21
06:06 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
11/21
06:05 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
11/21
06:00 am
zyme
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Medium
Report
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
11/7
07:12 am
zyme
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.
Medium
Report
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.
11/5
06:00 am
zyme
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors
Low
Report
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors
11/4
12:44 pm
zyme
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Citigroup Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Citigroup Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
11/1
09:18 am
zyme
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year [Yahoo! Finance]
Medium
Report
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year [Yahoo! Finance]
11/1
08:15 am
zyme
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/1
07:46 am
zyme
Zymeworks Inc. (NYSE: ZYME) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
10/31
04:05 pm
zyme
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
10/29
06:00 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
10/28
10:11 am
zyme
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Stifel Nicolaus from $21.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Stifel Nicolaus from $21.00 to $28.00. They now have a "buy" rating on the stock.
10/25
06:12 am
zyme
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference [Financial Post (Toronto, Ontario, Canada)]
10/25
06:00 am
zyme
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Low
Report
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
10/22
08:32 am
zyme
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/21
06:09 am
zyme
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers [Financial Post (Toronto, Ontario, Canada)]
10/21
06:00 am
zyme
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Low
Report
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
10/10
06:44 am
zyme
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 [Financial Post (Toronto, Ontario, Canada)]
10/10
06:30 am
zyme
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Low
Report
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
9/27
02:50 pm
zyme
Zymeworks Approaching A Moment Of Truth With Zanidatamab [Seeking Alpha]
Neutral
Report
Zymeworks Approaching A Moment Of Truth With Zanidatamab [Seeking Alpha]
9/25
08:09 am
zyme
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "neutral" rating on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "neutral" rating on the stock.
9/18
08:05 am
zyme
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/18
06:09 am
zyme
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference [Financial Post (Toronto, Ontario, Canada)]
9/18
06:00 am
zyme
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Low
Report
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference